Literature DB >> 16801482

Renal damage in primary aldosteronism: results of the PAPY Study.

Gian Paolo Rossi1, Giampaolo Bernini, Giovambattista Desideri, Bruno Fabris, Claudio Ferri, Gilberta Giacchetti, Claudio Letizia, Mauro Maccario, Massimo Mannelli, Mee-Jung Matterello, Domenico Montemurro, Gaetana Palumbo, Damiano Rizzoni, Ermanno Rossi, Achille Cesare Pessina, Franco Mantero.   

Abstract

Primary aldosteronism (PA) has been associated with cardiovascular hypertrophy and fibrosis, in part independent of the blood pressure level, but deleterious effects on the kidneys are less clear. Likewise, it remains unknown if the kidney can be diversely involved in PA caused by aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism (IHA). Hence, in the Primary Aldosteronism Prevalence in Italy (PAPY) Study, a prospective survey of newly diagnosed consecutive patients referred to hypertension centers nationwide, we sought signs of renal damage in patients with PA and in comparable patients with primary hypertension (PH). Patients (n = 1180) underwent a predefined screening protocol followed by tests for confirming PA and identifying the underlying adrenocortical pathology. Renal damage was assessed by 24-hour urine albumin excretion (UAE) rate and glomerular filtration rate (GFR). UAE rate was measured in 490 patients; all had a normal GFR. Of them, 31 (6.4%) had APA, 33 (6.7%) had IHA, and the rest (86.9%) had PH. UAE rate was predicted (P < 0.001) by body mass index, age, urinary Na+ excretion, serum K+, and mean blood pressure. Covariate-adjusted UAE rate was significantly higher in APA and IHA than in PH patients; there were more patients with microalbuminuria in the APA and IHA than in the PH group (P = 0.007). Among the hypertensive patients with a preserved GFR, those with APA or IHA have a higher UAE rate than comparable PH patients. Thus, hypertension because of excess autonomous aldosterone secretion features an early and more prominent renal damage than PH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801482     DOI: 10.1161/01.HYP.0000230444.01215.6a

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  130 in total

Review 1.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

2.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

3.  Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.

Authors:  Wei Liang; Cheng Chen; Jing Shi; Zhilong Ren; Fengqi Hu; Harry van Goor; Pravin C Singhal; Guohua Ding
Journal:  Nephrol Dial Transplant       Date:  2010-08-20       Impact factor: 5.992

4.  Classics in Cardiovascular Endocrinology: Aldosterone Action Beyond Electrolytes.

Authors:  Richard J Auchus
Journal:  Endocrinology       Date:  2015-12-23       Impact factor: 4.736

Review 5.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

Review 6.  Primary aldosteronism.

Authors:  Richard J Auchus; Fiemu E Nwariaku
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

7.  Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage.

Authors:  G Liu; G-S Yin; J-y Tang; D-J Ma; J Ru; X-H Huang
Journal:  J Hum Hypertens       Date:  2014-02-20       Impact factor: 3.012

Review 8.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

9.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 10.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.